MERIT - Menopause: Evidence on Risks and benefits for Individualized Therapies

Purpose and Goals
Many women experience troublesome symptoms around menopause, such as hot flashes, sleep problems, mood changes, and reduced quality of life. Hormone therapy for menopause can relieve these symptoms in most women. However, use of hormone therapy dropped sharply after a large study in 2002 suggested that it might increase the risk of breast cancer and heart disease. Later research has not clearly confirmed these risks, but uncertainty still exists—especially for newer types of hormone treatments.
This project aims to better understand how menopausal hormone therapy is used in Sweden today and whether different types of treatment are linked to different health outcomes. The overall goal is to support safer, more personalized treatment for women.
The project includes three parts:
- Part 1: National surveys of women and healthcare professionals about their knowledge, attitudes, and experiences with menopausal hormone therapy.
- Part 2: Studies using national health registers to examine trends in hormone therapy use and possible links to cancer, heart disease, and mental health.
- Part 3: A clinical trial comparing two commonly used progesterone treatments to see how they affect the body, mood, and quality of life.
The results will help fill important knowledge gaps and contribute to updated treatment guidelines, with the aim of improving care and quality of life for women going through menopause.
Study Design
This project combines several research methods to give a broad and reliable picture of menopausal hormone therapy in Sweden.
- Aim 1 (Part 1):
Use nationwide online surveys and interviews to explore what women and clinicians know and think about hormone therapy, how it is prescribed, and how easy it is to access care. The studies will also examine whether current Swedish guidelines are being followed.
- Aim 2 (Part 2):
Analyze national health register data from 2006–2025 to study patterns of hormone therapy use and possible associations with cancer, heart disease, and mental health. Different types of hormone treatments and background factors (such as age and socioeconomic status) will be considered.
- Aim 3 (Part 3):
Conduct a clinical trial in multiple centers including 520 women during which women will be randomly given one of two treatments, and neither they nor the researchers know which one. The trial will compare estrogen combined with either micronized progesterone or norethisterone acetate. Researchers will study effects on breast and uterine health, metabolism, mood, and quality of life.
Together, these studies will provide strong evidence to support safer and more individualized use of menopausal hormone therapy in Sweden.
Join our panel of People with Lived Experiences (PWLE)
If you are interested, please contact Ourania Chinopoulou (ourania.chinopoulou@uu.se; for Swedish speakers) or Malgorzata (Margot) Tybuszewska (malgorzata.tybuszewska@uu.se; for English speakers)
Upcoming Events Featuring the MERIT Team
- 3rd Sex as a Biological Variable Symposium
EU-SABV 23-24 June 2026, Zurich, Switzerland - The Nordic Federation of Societies of Obstetrics and Gynecology Congress
NFOG 24-27 August 2027, Tampere, Finland - Svensk Förening för Obstetrik och Gynekologi
SFOG Congress 24-27 August 2026, Stockholm
Contact person
Project leader
Prof. Alkistis Skalkidou
Department of Women’s and Children’s Health, Uppsala University
Email: alkistis.skalkidou@uu.se


